These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4426403)

  • 1. Progestasert: a uterine therapeutic system for long-term contraception: I. Philosophy and clinical efficacy.
    Pharriss BB; Erickson R; Bashaw J; Hoff S; Place VA; Zaffaroni A
    Fertil Steril; 1974 Nov; 25(11):915-21. PubMed ID: 4426403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with the uterine progesterone system (Progestasert R).
    Zador G; Nilsson BA; Nilsson B; Sjöberg NO; Weström L; Wiese J
    Contraception; 1976 May; 13(5):559-69. PubMed ID: 1261259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Steroid intra-uterine contraception: progesterone-releasing devices. II. Insertion, clinical problems and contraceptive dependability].
    Custo GM; Cosmi EV
    Patol Clin Ostet Ginecol; 1984; 12(4):331-43. PubMed ID: 12340352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrauterine devices containing progesterone.
    Murad F
    Drug Ther (NY); 1977 May; 7(5):119-21. PubMed ID: 12277687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine therapeutic system for long-term contraception: II. Clinical correlates.
    Martinez-Manautou J; Aznar R; Maqueo M; Pharriss BB
    Fertil Steril; 1974 Nov; 25(11):922-6. PubMed ID: 4426404
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible contraception for the woman over 35 years of age.
    Archer DF
    Curr Opin Obstet Gynecol; 1992 Dec; 4(6):891-6. PubMed ID: 1450355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study.
    Shaw ST; Macaulay LK; Aznar R; González-Angulo A; Roy S
    Am J Obstet Gynecol; 1981 Dec; 141(7):821-7. PubMed ID: 7315908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cortisol level in lactating women using Progestasert system.
    Askalani H; Badraoui MH; Mahrous T; Osman MI; Bayad MA; Ibrahim II; Abdalla MI
    Popul Sci; 1981; (2):109-14. PubMed ID: 12339476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactation pattern in Egyptian women using the Progestasert system.
    Badraoui MH; Askalani H; Mahrous I; Serour G; Hefnawi F
    Contracept Deliv Syst; 1982 Jan; 3(1):53-60. PubMed ID: 12264128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of the Progestasert TM 65 progesterone therapeutic system for contraception.
    Place VA; Pharriss BB
    J Reprod Med; 1974 Aug; 13(2):66-8. PubMed ID: 4844516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill.
    Vessey MP; Lawless M; McPherson K; Yeates D
    Lancet; 1983 Oct; 2(8356):930-4. PubMed ID: 6138502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study of a progesterone-releasing intrauterine contraceptive device.
    Brenner PF; Cooper DL; Mishell DR
    Am J Obstet Gynecol; 1975 Mar; 121(5):704-6. PubMed ID: 1115173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with two different medicated intrauterine devices: a comparative study of the Progestasert and Nova-T.
    Fylling P; Fagerhol M
    Fertil Steril; 1979 Feb; 31(2):138-41. PubMed ID: 761675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate postplacental insertion of GYNE-T 380 and GYNE-T 380 postpartum intrauterine contraceptive devices: randomized study.
    Tatum HJ; Beltran RS; Ramos R; Van Kets H; Sivin I; Schmidt FH
    Am J Obstet Gynecol; 1996 Nov; 175(5):1231-5. PubMed ID: 8942493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the Progestasert on the menstrual pattern, ovarian steroids and endometrium.
    Wan LS; Hsu YC; Ganguly M; Bigelow B
    Contraception; 1977 Oct; 16(4):417-34. PubMed ID: 923252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic inflammatory disease among women using copper IUDs, Progestasert, oral contraceptive pills or vaginal contraceptive pills: a 4-year prospective investigation.
    Larsson B; Rodau S; Patek E
    Contracept Deliv Syst; 1981 Jul; 2(3):237-42. PubMed ID: 12278910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prolactin levels in lactating women using progestasert system.
    Badraoui MH; Askalani H; Mahrous I; Osman MI; Bayad MA; Ibrahim II; Abdalla MT
    Popul Sci; 1981; (2):115-20. PubMed ID: 12339477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intrauterine device today.
    Rioux JE
    J SOGC; 1993 Oct; 15(8):921-4. PubMed ID: 12318529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.